3SBio is a fully-integrated biotechnology company in China with market-leading biopharmaceutical franchises in oncology, auto-immune diseases and nephrology. TPIAO, the only commercialized recombinant human thrombopoietin ("rhTPO") product in the world; Yisaipu, the first-to-market recombinant human tumor necrosis factor-α receptor II (TNFR) – IgG Fc fusion protein for the treatment of rheumatoid arthritis; and EPIAO and SEPO, recombinant human erythropoietin ("rhEPO") products. 3SBio has also licensed the China commercial rights to AstraZeneca's Byetta/Bydureon and Eli Lilly's Humulin. 3SBio is focused on building an innovative product pipeline, with over 16 National Class 1 candidates under development. 3SBio manufacturing capabilities include recombinant proteins, monoclonal antibodies and chemically synthesized molecules, with production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Como, Italy. 3SBio is actively pursuing international expansion through acquisition, licensing and partnerships.